You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
京新藥業(002020.SZ):EVT201膠囊主要研究終點結果達到方案預設的優效標準
格隆匯 11-05 18:11

格隆匯11月5日丨京新藥業(002020.SZ)公佈,近日,公司研發的EVT201膠囊治療失眠障礙的隨機、雙盲、安慰劑對照、多中心的Ⅲ期臨牀研究(JX202001-EVT201-III)主要研究終點結果達到方案預設的優效標準。研究結果表明,EVT201膠囊可以顯著延長失眠患者的總睡眠時間。

目前失眠障礙治療藥物主要包括地西泮、氯硝西泮等在內的苯二氮卓類,以及唑吡坦(國內1995年上市)、右佐匹克隆(國內2007年上市)為代表的新型非苯二氮卓類。此後,國內無新藥獲批上市。

截至目前,公司在EVT201項目上累計已投入研發費用約為1.86億元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account